"This collaboration with MEEI is another example of our strategy to work with top research groups in the world to accelerate human stem cell research", said Stem Cell Innovations CEO Dr. James Kelly. "As our PluriCells do not fall under the Presidential ban, there is a lot of interest from the academic world to get access to our human pluripotent stem cell platform".
"Exploring the potential of PluriCells for our research is really exciting", said Dr. Albert Edge. "Until now, our research was hampered by a lack of good quality human stem cells".
Stem Cell Innovations recently disclosed it has produced multiple lines of human pluripotent stem cells. These PluriCell lines can be efficiently cultured in tissue culture plates without the use of feeder layers and can be efficiently differentiated into multiple cell-types, having the potential to aid in drug discovery and development.
PluriCells are a type of pluripotent stem cells isolated from fetal tissue that have the ability to become all cell types of the body. Because they are developed from fetal germ cells, not viable embryos, they are eligible to be used in any NIH funded laboratory. Stem cells derived from fetal germ cells were explicitly excluded from the Presidential ban by the Department of Health and Human Services guidance document of March 19, 2002, that laid out what type of stem cells could and could not be used in Federally funded research (for the actual document see: http://www.hhs.gov/ohrp/humansubjects/guidance/stemcell.pdf).
About Stem Cell Innovations, Inc. SCI is a cell biology company with facilities in Scotch Plains, N.J., Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations' proprietary, human pluripotent stem cells, known as PluriCells(TM), have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.
Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell technology greatly expands the Company's currently marketed C3A human liver cell-based toxicology offerings.
Additional information is available at www.stemcellinnovations.com.
Contact Stem Cell Innovations: Dr. James H. Kelly, +1 281-679-7900 or Ivo Piest, +31 71 8010 (Europe)
PluriCells is a Trademark of Stem Cell Innovations, Inc.
About Massachusetts Eye and Ear Infirmary Located in Boston, Massachusetts, the Infirmary is a 42-bed independent specialty hospital founded in 1824. The Infirmary has earned an international reputation for its successful treatment of the most difficult diseases and conditions of the eye, ear, nose, throat, head and neck, and for its outstanding contributions to medical research and education.
The primary teaching hospital for Harvard Medical School in ophthalmology and otolaryngology, the Infirmary trains more than 110 residents and fellows each year in our various sub-specialties, including cornea, neuro-ophthalmology, retina, eye pathology, pediatrics, glaucoma, ocular oncology, immunology, head and neck surgery and oncology, pediatric otolaryngology, facial plastics, otology and oto-neurology.
The Infirmary has received many honors over the years. U.S. News & World Report magazine has ranked the Infirmary in the top five in one or both of its specialties (ophthalmology and otolaryngology) each year since the magazine began publishing its annual survey of hospitals in 1990.
Contact MEEI: Dr. Albert Edge, +1 617-573-4452
Forward Looking Statement This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because theses forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.
If any one or more or these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
http://hugin.info/136566/R/1080370/186911.pdf
© 2006 Dow Jones News
